FDA Puts Cumberland’s Ifetroban on Fast Track for Cardiomyopathy in DMD The US FDA granted Fast Track designation to ifetroban, an oral thromboxane receptor antagonist, for cardiomyopathy in patients with DMD.

Cumberland Pharmaceuticals announced that the @fda.gov has granted #FastTrack Designation to #Ifetroban (#Dyscorban®), the company’s novel oral therapy for #Cardiomyopathy in patients with #DuchenneMuscularDystrophy (DMD).

Read more: https://bit.ly/4rTzo4j

#RareDisease #DMD #MedSky

Cumberland Pharmaceuticals Advances Duchenne Muscular Dystrophy Treatment with FDA's Fast Track Designation Cumberland Pharmaceuticals has received FDA Fast Track Designation for its oral therapy targeting heart disease in Duchenne Muscular Dystrophy, speeding up development for urgent medical need.

Cumberland Pharmaceuticals Advances Duchenne Muscular Dystrophy Treatment with FDA's Fast Track Designation #USA #Nashville #ifetroban #DMD #Cumberland_Pharma

Cumberland Pharmaceuticals Unveils Promising Phase 2 FIGHT DMD Trial Findings at PPMD Annual Conference Cumberland Pharmaceuticals presented notable Phase 2 FIGHT DMD trial results showcasing ifetroban's potential benefits for patients with Duchenne muscular dystrophy heart disease at the PPMD conference.

Cumberland Pharmaceuticals Unveils Promising Phase 2 FIGHT DMD Trial Findings at PPMD Annual Conference #USA #Nashville #Cumberland #ifetroban #DMD

Cumberland Pharmaceuticals Showcases Breakthrough DMD Trial Results at MDA Conference Cumberland Pharmaceuticals has presented promising findings from its FIGHT DMD trial at the MDA conference, showing significant cardiac improvements in DMD patients.

Cumberland Pharmaceuticals Showcases Breakthrough DMD Trial Results at MDA Conference #USA #Dallas #Cumberland_Pharmaceuticals #ifetroban #DMD

Cumberland Pharmaceuticals Achieves Landmark Success in DMD Heart Disease Trial with Ifetroban Cumberland Pharmaceuticals reports significant progress in treating Duchenne muscular dystrophy heart disease, marking an important milestone for DMD patients using ifetroban.

Cumberland Pharmaceuticals Achieves Landmark Success in DMD Heart Disease Trial with Ifetroban #USA #Nashville #Cumberland_Pharmaceuticals #Duchenne_Muscular_Dystrophy #ifetroban